Halozyme Therapeutics (HALO) to Release Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) is expected to announce its Investor update results after the market closes on Tuesday, February 17th. Analysts expect Halozyme Therapeutics to post earnings of $1.92 per share and revenue of $446.1320 million for the quarter. Investors can check the company’s upcoming Investor update earning summary page for the latest details on the call scheduled for Wednesday, January 28, 2026 at 8:30 AM ET.

Halozyme Therapeutics Stock Performance

HALO stock opened at $79.44 on Monday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The company has a market capitalization of $9.34 billion, a price-to-earnings ratio of 16.72, a P/E/G ratio of 0.33 and a beta of 0.97. Halozyme Therapeutics has a 12 month low of $47.50 and a 12 month high of $82.22. The firm has a 50 day moving average of $70.85 and a two-hundred day moving average of $69.96.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of recent research reports. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, December 4th. JPMorgan Chase & Co. increased their price objective on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Morgan Stanley cut their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research note on Monday, October 20th. Finally, Citizens Jmp boosted their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $78.80.

Insider Buying and Selling

In related news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at $55,733,662.16. This represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the sale, the director directly owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 49,398 shares of company stock worth $3,650,592 in the last ninety days. Insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. StoneX Group Inc. lifted its stake in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 132 shares during the period. Coldstream Capital Management Inc. raised its holdings in Halozyme Therapeutics by 1.9% in the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 165 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the period. Private Advisor Group LLC grew its holdings in shares of Halozyme Therapeutics by 0.8% during the 3rd quarter. Private Advisor Group LLC now owns 23,623 shares of the biopharmaceutical company’s stock worth $1,733,000 after purchasing an additional 184 shares in the last quarter. Finally, UMB Bank n.a. grew its holdings in shares of Halozyme Therapeutics by 18.2% during the 4th quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 200 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.